Paul Peter Tak

CEO
Kintai Therapeutics

Professor Paul Peter Tak MD PhD FMedS is currently CEO of Kintai Therapeutics and Venture Partner at Flagship Pioneering, Professor of Medicine at the Amsterdam University Medical Centre (AMC), Honorary Professor of Rheumatology at Ghent University and Honorary Senior Visiting Fellow at the University of Cambridge. He received his medical degree cum laude from the Free University in Amsterdam and was trained as an internist, rheumatologist and immunologist at Leiden University Medical Center, where he also received his PhD. At GlaxoSmithKline he served as Senior Vice President, Chief Immunology Officer, and Global Development Leader, overseeing the creation of a portfolio of potential medicines for immune-mediated inflammatory diseases and pain. He established Arthrogen b.v., Amsterdam, a biotech company developing intra-articular gene therapy and has been CEO of Tempero Pharmaceuticals. He is also one of the founders and board directors of Sitryx Therapeutics, and serves on the board of directors of Levicept.